Us – Amyloidosis Foundation
Supporting amyloidosis patients and their families while promoting research, education and awareness. www.amyloidosis.org 1-877-AMYLOID info@amyloidosis.org
Supporting amyloidosis patients and their families while promoting research, education and awareness. www.amyloidosis.org 1-877-AMYLOID info@amyloidosis.org
Gerard Walls, MB MRCP MSc FRCR, Queens University in Belfast, UK, discusses the NI-HEART analysis aimed at addressing the challenges of collecting cardiac toxicity events…
Ernst Holler, MD, University Hospital Regensburg, Regensburg, Germany, gives an overview of the relationship between the gut microbiome and graft-versus-host disease (GvHD). A loss of…
October, 2024, will see the 10-year anniversary of The Lancet Haematology, which was first published in 2014. To mark this occasion, we are publishing a…
Frontline nivolumab plus chemotherapy has been recommended for approval in unresectable or metastatic urothelial carcinoma.
Robert W. Mutter, MD, discusses personalized treatment approaches with radiation and endocrine therapy with
The phase 2 DENALI trial is investigating azenosertib in patients with high-grade serous ovarian cancer.
Kian-Huat Lim, MD, PhD, discusses the current treatment landscape for metastatic pancreatic cancer.
Glecirasib elicited responses and demonstrated a manageable safety profile in patients with pretreated advanced NSCLC harboring KRAS G12C mutations.
R. Lor Randall, MD, FACS, discusses research examining ALDH1A1 and CD44, potential markers of osteosarcoma stem cells, and how further research may be warranted with…
Benjamin Tomlinson, MD, discusses the first-line approval of luspatercept and other ongoing research in low-risk MDS.